Thrombocytopenia-Absent Radius Syndrome Medication

Updated: Mar 07, 2019
  • Author: John K Wu, MBBS, MSc, FRCPC; Chief Editor: Hassan M Yaish, MD  more...
  • Print
Medication

Medication Summary

The use of antifibrinolytic agents and synthetic antidiuretic hormones may be indicated.

Next:

Antifibrinolytic agents

Class Summary

Antifibrinolytic agents decrease bleeding and transfusion requirements and help establish hemostasis. They are especially useful for controlling bleeding or prolonged oozing from gingival surfaces (eg, during teething in infants).

Aminocaproic acid (Amicar)

Competitively inhibits activation of plasminogen to plasmin.

Tranexamic acid (Cyklokapron)

Competitively inhibits activation of plasminogen to plasmin.

Previous
Next:

Synthetic antidiuretic hormones

Class Summary

Synthetic antidiuretic hormones nonspecifically enhance hemostasis by stimulating the release of von Willebrand factor. Desmopressin stimulates the release of factor VIII, prostaglandins, and plasminogen. However, the mechanism of action is not clear, and it may not be common to all 3 substances. These agents affect vascular walls, increasing platelet adhesion. This local hemostatic action may account for their hemostatic properties.

Desmopressin acetate (DDAVP)

Increases plasma factor VIII levels, promoting platelet aggregation. Intranasal route not recommended because of unproven efficacy in small infants. Only concentrated form (150 mcg/spray) enhances hemostasis.

Previous